This manuscript presents the efforts to prevent recurrence of stroke by using hydroxyurea and red cell exchange therapy after developing early signs of a new neurological attack in a patient with Moyamoya syndrome.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Moyamoya syndrome may occur several years after cerebrovascular event in patients with sickle cell disease.
📊
Key Findings & Data:Moyamoya syndrome may occur several years after cerebrovascular event in patients with sickle cell disease.
💡
Conclusion & Impact:This manuscript presents the efforts to prevent recurrence of stroke by using hydroxyurea and red cell exchange therapy after developing early signs of a new neurological attack in a patient with Moyamoya syndrome.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Moyamoya syndrome may occur several years after cerebrovascular event in patients with sickle cell disease. This manuscript presents the efforts to prevent recurrence of stroke by using hydroxyurea and red cell exchange therapy after developing early signs of a new neurological attack in a patient with Moyamoya syndrome.
Özet
Moyamoya sendromu orak hücreli anemi hastalarında serebrovasküler olaylardan yıllar sonra gelişebilir. Bu çalışmada yeni bir nörololojik atağın öncü işaretleri gelişen ve Moyamoya sendromu olan hastada, hidroksiüre ve eritrosit değişimi ile inme oluşmasını önleme çabaları sunulmaktadır.
🔖
Cite This Article
ASMA, S., YERAL, M., KASAR, M., TAN, M., BOĞA, C., ULUSAN, Ş. N. (2022). Moyamoya sendromu olan orak hücreli anemi hastasında tekralayan inmelerin önlenmesi. Gaziantep Tıp Dergisi, Cilt: 19 - Sayı: 3, 205–206. https://ajindex.com/articles/518867
Dobson SR, Holden KR, Nietert PJ, Cure JK, Laver JH, Disco D, et al. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 2002;99(9):3144-50
Kim JM, Lee SH, Roh JK. Changing ischaemic lesion patterns in adult moyamoya disease. J Neurol Neurosurg Psychiatry 2009;80(1):36-40
Metcalfe SA, Barlow-Stewart K, Campbell J, Emery J. Genetics and blood-hemoglobinopathies and clotting disorders. Aust Fam Physician 2007;36(10):812-9
Bhattacharyya M, Kannan M, Chaudhry VP, Mahapatra M, Pati H, Saxena R. Hypercoagulable state in five thalassemia intermedia patients. Clin Appl Thromb Hemost 2007;13(4):422- 7
Singh R, Venketesubramanian N. Recurrent cerebral infarction in beta thalassaemia major. Cerebrovasc Dis 2004;17(4):344-5
Mukherje A. Moyamoya disease and beta-thalassemia. J Assoc Physicians India 1995;43(10):710-1
Sanefuji M, Ohga S, Kira R, Yoshiura T, Torisu H, Hara T. Moyamoya syndrome in a splenectomized patient with beta- thalassemia intermedia. J Child Neurol 2006;21(1):75-7
Owecki M, Wegrzyn D, Kozubski W. Ischemic manifestation of adult moyamoya disease: a case report. Neurol Neurochir Pol 2003;37(2):419-27
Gorrotxategi P, Reguilón MJ, Gaztañaga R. Moya-moya disease in a child with multiple malformations. Rev Neurol 1995;23(120):403-5.